PUBLIC SUMMARY DOCUMENT
Product: Diamonds Gelling Sachets with ActiveOne Odour Control
Applicant: ConvaTec (Australia) Pty Ltd
Date of SPAP Meeting: 25 November 2014
1. Proposed Listing on the Stoma Appliance Scheme
The applicant, ConvaTec, sought listing of Diamonds Gelling Sachets with ActiveOne Odour Control in Subgroup 9(m) of the Stoma Appliance Scheme (SAS) Schedule. The product was proposed for listing at the unit price of $0.083, with a maximum quantity of 600 sachets per annum.
2. Comparator
The applicant nominated Omnigon Eakin Perform, a product currently listed in Subgroup 9(m) with (SAS code 9754J), as the comparator. The comparator is listed at the unit price of $0.083, with a maximum quantity of 720 per annum.
3. Background
This was the Stoma Product Assessment Panel (SPAP)’s first consideration of this product.
4. Clinical Place for the Product
SPAP agreed that the proposed product provides an alternative for users requiring thickening agents in managing high liquid output. However, it was noted that a broader review of clinical effectiveness is currently being undertaken for products in Group9.
5. SPAP Comment
Clinical Analysis
The SPAP noted that the proposed product has the added benefit of activated carbon compounds which may reduce odour. The Panel also noted that the product provides benefits to ostomates which is likely to improve quality of life by reducing pouch ballooning, noise and leakage.
The Panel noted that no clinical data was presented.
Economic Analysis
Not undertaken.
Financial Analysis
As the proposed product is recommended for listing at a lower price compared with the nominated comparator in Subgroup 9(m), listing the product would result in a cost reduction to Government.
6. SPAP Recommendation
The SPAP recommended that the Diamonds Gelling Sachets with ActiveOne Odour Control be listed in Subgroup 9(m) of the SAS Schedule at the unit price of $0.083, with a maximum quantity of 600 sachets per annum.
However, the Panel noted that all recommendations for products to be listed in Group 9 of the SAS Schedule may be subject to change as a result of the outcomes from the Group 9 Review. The outcomes of the Group 9 Review are expected in 2015.
7. Context for Decision
The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.
8. Applicant’s Comment
ConvaTec (Australia) Pty Ltd agrees with the SPAP’s recommendation contained in the Public Summary Document.
CC#3